The Pharmalot blog reports on new drugs introduced at the ACS Meeting in Boston -- and unfortunately on the lack of innovation exhibited by these drugs. Fifty-eight drugs were introduced and not ONE was directed toward a previously unidentified target. Yikes!
This is consistent with a post I made a couple of days ago based on information from the In the Pipeline blog. This analyzed 252 drugs and determined 58% were from pharma (vs. biotech or univiersities) but only 36% of pharma's drugs were classified as innovative (vs 65% and 62% for biotech and universities respectively).
Citeline's Ian Lloyd commented, "There is much talk in the industry about the move towards focusing on new and innovative therapies, especially in orphan conditions, but the hard evidence is failing to match the rhetoric.”
Posted by Bruce Lehr November 10th 2010.